REDUCING PATHOLOGY IN ALZHEIMER’S DISEASE THROUGH ANGIOTENSIN TARGETING
Welcome to the RADAR Trial website which is designed to provide some additional information about our trial and where people who are interested to find out more on how to take part.
Alzheimer's disease is the most common form of dementia that affects memory and brain function in older individuals. The disease starts slowly and worsens to the extent that people eventually need 24-hour care - a heart-breaking, exhausting and often costly reality for family and health services. With an ageing population, Alzheimer's disease care provision needs are predicted to increase, which will greatly impact on NHS healthcare costs.
What is this drug trial testing?
Losartan (a tablet commonly used to treat blood pressure) will be compared to placebo (a harmless sugar pill) to see if it reduces the progression of brain damage in Alzheimer’s disease irrespective of whether participants have high blood pressure or not.
Alzheimer's disease is the most common form of dementia that affects memory and brain function in older individuals. The disease starts slowly and worsens to the extent that people eventually need 24-hour care - a heart-breaking, exhausting and often costly reality for family and health services. With an ageing population, Alzheimer's disease care provision needs are predicted to increase, which will greatly impact on NHS healthcare costs.
What is this drug trial testing?
Losartan (a tablet commonly used to treat blood pressure) will be compared to placebo (a harmless sugar pill) to see if it reduces the progression of brain damage in Alzheimer’s disease irrespective of whether participants have high blood pressure or not.
How is this study funded?
Thanks to funding of nearly £2 million by the Medical Research Council (MRC) and managed by the National Institute for Health Research*, the double blinded placebo-controlled randomised trial, known as RADAR (Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting), will recruit approximately 230 participants from a number of sites across the UK.
Thanks to funding of nearly £2 million by the Medical Research Council (MRC) and managed by the National Institute for Health Research*, the double blinded placebo-controlled randomised trial, known as RADAR (Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting), will recruit approximately 230 participants from a number of sites across the UK.
